Juvenile Absence Epilepsy
📧 Sign up to get email alerts when something new happens for Juvenile Absence Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-04Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]
Phase 3 trial evaluating brivaracetam as monotherapy in children aged 2–25 with Childhood Absence Epilepsy or Juvenile Absence Epilepsy has …
-
CLINICAL_TRIALS trial_result · 2026-07-31Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]
Phase 3 clinical trial evaluating brivaracetam as monotherapy in children and adolescents with childhood absence epilepsy or juvenile absenc…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]
Phase 3 trial evaluating brivaracetam as monotherapy in children and adolescents with childhood absence epilepsy or juvenile absence epileps…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]
Clinical trial update notes a Phase 3 study evaluating the long-term safety and tolerability of brivaracetam in children with Childhood abse…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]
Phase 3 study evaluating brivaracetam as monotherapy in children and young adults with Childhood Absence Epilepsy or Juvenile Absence Epilep…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]
A Phase 3 trial evaluating long-term safety, tolerability, and efficacy of brivaracetam in children aged 2 to 26 years with childhood absenc…